Coherence Neuro, a startup developing brain implants to treat cancer, has raised $45 million in a Series A funding round co-led by Peter Thiel's Founders Fund and the OpenAI Startup Fund. The investment, which also included Lux Capital, Olive Capital and 8VC, will enable the company to conduct its first chronic human trial of its implant as a treatment for glioblastoma, an aggressive brain cancer. In a post, Coherence explained that the funds will also support its pursuit of FDA breakthrough device designation and expansion into other conditions such as pancreatic cancer and other malignancies. The announcement matters because it represents a significant vote of confidence from high-profile investors in a novel approach to cancer treatment that could upend traditional methods.
Glioblastoma is one of the most lethal forms of brain cancer, with a grim prognosis; its victims include Senator Ted Kennedy and Senator John McCain. The standard of care involves surgery, radiation and chemotherapy, but recurrence is nearly universal. Coherence's implant, called SOMA, is a button-sized device that monitors electrical signals emitted by cancerous cells and delivers electrical signals to disrupt tumor development. It works with a removable wearable placed above the ear and an app that tracks symptoms and therapy history. Several consenting patients have had the device implanted during surgery to remove glioblastoma tumors, with initial tests focused on safety. The new funding will allow the company to move beyond these acute tests to a chronic trial, a critical step toward commercialization.
The technology is based on research showing that tumors have unique electrical signals and fields. By disrupting this electrical activity, Coherence aims to arrest cancer development before it becomes advanced. If successful, the implant could change the grim prognosis that glioblastoma patients face upon diagnosis. The involvement of the OpenAI Startup Fund, which typically invests in AI-driven companies, suggests that Coherence may be leveraging artificial intelligence to analyze the electrical signals and optimize treatment. This could lead to personalized, adaptive therapies that learn from each patient's tumor activity.
As Coherence advances its R&D, other entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also developing novel medications for brain cancers. The broader biotech sector, as covered by BioMedWire, a specialized communications platform for the life sciences, continues to see innovation in cancer treatment. Coherence's approach, if validated, could complement existing therapies and offer a new modality that is both diagnostic and therapeutic. The company is also expanding its team to support these efforts, hiring operators and builders to accelerate development.
The Series A round is a strong signal that investors are willing to bet on unconventional solutions for unmet medical needs. With Peter Thiel's Founders Fund and the OpenAI Startup Fund backing the company, Coherence Neuro is positioned to make significant strides in the fight against cancer. The results of the chronic human trial will be closely watched by the medical community, as they could mark the beginning of a new era in cancer treatment. For more information on BioMedWire and its parent IBN, visit their website.
